The European Medicines Agency will begin a marketing authorization application review for Rhokiinsa after accepting the drug application from Aerie Pharmaceuticals, the company announced in a press release.
Rhokiinsa (netarsudil ophthalmic solution 0.02%), marketed as Rhopressa in the United States, is indicated for the reduction of IOP in open-angle glaucoma or ocular hypertension.
“We are delighted that the European regulatory authorities have accepted our Rhokiinsa filing for review. If Rhokiinsa is approved, we plan to submit an MAA for Roclatan shortly thereafter,” Aerie
Uncategorized